Compare Fox Corp Class A (FOXA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Sana Biotechnology Inc — how do they compare? Fox Corp Class A trades at $62.76 (market cap $25.36B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Fox Corp Class A is far larger — about 30.3× Sana Biotechnology Inc's market cap, and Fox Corp Class A pays a 0.91% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Sana Biotechnology Inc for 23 Days on average.
| FOXA | SANA | |
|---|---|---|
Market Cap | $25.36B | $836.71M |
Volume | 2,566,954 | 4,507,444 |
Sector | Media | Health |
52-Week High | $76.11 | $5.92 |
52-Week Low | $48.79 | $2.68 |
Typical Hold Time | 34 Days | 23 Days |
Enterprise Value | $28.72B | $749.96M |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.42, up 1.15% with a bullish technical signal and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats and solid profitability metrics including 14.29% ROE and 9.84% net margin. Recent news highlights the pending Roku acquisition and regulatory scrutiny, while institutional activity shows CEO Lachlan Murdoch's significant $10.3 million share purchase in September 2026.
The outlook remains positive with a $72 consensus price target representing 13.5% upside potential. Key opportunities include continued earnings growth and strategic acquisitions, while risks center on regulatory approval for the Roku deal and potential market volatility. With no analyst sell ratings and strong institutional support, FOXA presents a compelling investment case in the media sector.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
